Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal antithrombotic strategy after PCI or ACS in atrial fibrillation
NL-OMON51815Phase 4Recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of edoxaban and aspirin in Atrial fibrillation (AFib), acute coronary syndrome (ACS) and coronary arteriosclerosis (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoints: Primary safety endpoint and Primary efficacy endpoint. Started Jan 2023; status: recruiting.
02
Drugs
edoxabanaspirin
03
Conditions
Atrial fibrillation (AFib)acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON51815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51815.